{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:57:20Z","timestamp":1792727840937,"version":"4.5.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.gim.2021.10.013","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T21:28:15Z","timestamp":1638307695000},"page":"521-534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic review"],"prefix":"10.1016","volume":"24","author":[{"given":"Alexis Ceecee","family":"Britten-Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena A.","family":"Gocuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Cichello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"O\u2019Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doron G.","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren N.","family":"Ayton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gim.2021.10.013_bib1","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.ophtha.2017.04.008","article-title":"Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease","volume":"124","author":"Stone","year":"2017","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.gim.2021.10.013_bib2","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ophtha.2020.04.008","article-title":"Genetic basis of inherited retinal disease in a molecularly characterized cohort of more than 3000 families from the United Kingdom","volume":"127","author":"Pontikos","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.gim.2021.10.013_bib3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/13816810.2021.1913610","article-title":"Inherited retinal diseases are the most common cause of blindness in the working-age population in Australia","volume":"42","author":"Heath Jeffery","year":"2021","journal-title":"Ophthalmic Genet"},{"issue":"2","key":"10.1016\/j.gim.2021.10.013_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004015","article-title":"A\u00a0comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010","volume":"4","author":"Liew","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.gim.2021.10.013_bib5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.preteyeres.2018.08.003","article-title":"Gene therapy for visual loss: opportunities and concerns","volume":"68","author":"Lee","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.gim.2021.10.013_bib6","doi-asserted-by":"crossref","first-page":"100827","DOI":"10.1016\/j.preteyeres.2019.100827","article-title":"Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives","volume":"77","author":"Garafalo","year":"2020","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/ceo.13917","article-title":"Inherited retinal diseases: therapeutics, clinical trials and end points-a review","volume":"49","author":"Georgiou","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.gim.2021.10.013_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/08164622.2021.1880863","article-title":"Gene therapy for inherited retinal diseases: progress and possibilities","volume":"104","author":"Hu","year":"2021","journal-title":"Clin Exp Optom"},{"key":"10.1016\/j.gim.2021.10.013_bib9","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.gim.2021.10.013_bib10","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/jrsm.1060","article-title":"The effect direction plot: visual display of non-standardised effects across multiple outcome domains","volume":"4","author":"Thomson","year":"2013","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-020-1304-1","article-title":"The effect of human gene therapy for RPE65-associated Leber\u2019s congenital amaurosis on visual function: a systematic review and meta-analysis","volume":"15","author":"Wang","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"9701","key":"10.1016\/j.gim.2021.10.013_bib13","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(09)61836-5","article-title":"Age-dependent effects of RPE65 gene therapy for Leber\u2019s congenital amaurosis: a phase 1 dose-escalation trial","volume":"374","author":"Maguire","year":"2009","journal-title":"Lancet"},{"issue":"10097","key":"10.1016\/j.gim.2021.10.013_bib14","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib15","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ymthe.2017.09.014","article-title":"Safety and long-term efficacy of AAV4 gene therapy in patients with RPE65 Leber congenital amaurosis","volume":"26","author":"Le Meur","year":"2018","journal-title":"Mol Ther"},{"issue":"9","key":"10.1016\/j.gim.2021.10.013_bib16","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, safety, and durability of voretigene neparvovec-rzyl in RPE65 mutation-associated inherited retinal dystrophy: results of phase 1 and 3 trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archophthalmol.2011.298","article-title":"Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years","volume":"130","author":"Jacobson","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"20","key":"10.1016\/j.gim.2021.10.013_bib18","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa1414221","article-title":"Long-term effect of gene therapy on Leber\u2019s congenital amaurosis","volume":"372","author":"Bainbridge","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.gim.2021.10.013_bib19","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy","volume":"123","author":"Weleber","year":"2016","journal-title":"Ophthalmology"},{"issue":"21","key":"10.1016\/j.gim.2021.10.013_bib20","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber\u2019s congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.gim.2021.10.013_bib21","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1412965","article-title":"Improvement and decline in vision with gene therapy in childhood blindness","volume":"372","author":"Jacobson","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib22","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/mt.2009.277","article-title":"Gene therapy for Leber\u2019s congenital amaurosis is safe and effective through 1.5 years after vector administration","volume":"18","author":"Simonelli","year":"2010","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/j.gim.2021.10.013_bib23","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2","volume":"120","author":"Testa","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.gim.2021.10.013_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1475-925X-11-40","article-title":"Pupillometric analysis for assessment of gene therapy in Leber congenital amaurosis patients","volume":"11","author":"Melillo","year":"2012","journal-title":"Biomed Eng Online"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib25","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1167\/iovs.14-15895","article-title":"Pseudo-fovea formation after gene therapy for RPE65-LCA","volume":"56","author":"Cideciyan","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"39","key":"10.1016\/j.gim.2021.10.013_bib26","doi-asserted-by":"crossref","first-page":"15112","DOI":"10.1073\/pnas.0807027105","article-title":"Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics","volume":"105","author":"Cideciyan","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1016\/j.gim.2021.10.013_bib27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1089\/hum.2009.086","article-title":"Human RPE65 gene therapy for Leber congenital amaurosis: persistence of early visual improvements and safety at 1 year","volume":"20","author":"Cideciyan","year":"2009","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.1016\/j.gim.2021.10.013_bib28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum Gene Ther"},{"issue":"120","key":"10.1016\/j.gim.2021.10.013_bib29","doi-asserted-by":"crossref","first-page":"120ra15","DOI":"10.1126\/scitranslmed.3002865","article-title":"AAV2 gene therapy readministration in three adults with congenital blindness","volume":"4","author":"Bennett","year":"2012","journal-title":"Sci Transl Med"},{"issue":"10045","key":"10.1016\/j.gim.2021.10.013_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gim.2021.10.013_bib31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/978-3-319-17121-0_71","article-title":"Evaluation of ocular gene therapy in an Italian patient affected by congenital Leber amaurosis type 2 treated in both eyes","volume":"854","author":"Testa","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.gim.2021.10.013_bib32","first-page":"e7","article-title":"How long does gene therapy last? 4-year follow-up of phase 3 voretigene neparvovec trial in RPE65-associated LCA\/inherited retinal disease","volume":"23","author":"Drack","year":"2019","journal-title":"J\u00a0AAPOS"},{"issue":"8","key":"10.1016\/j.gim.2021.10.013_bib33","first-page":"4122","article-title":"Year 2 results for a phase 3 trial of voretigene neparvovec in biallelic RPE65-mediated inherited retinal disease","volume":"58","author":"Russell","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"21","key":"10.1016\/j.gim.2021.10.013_bib34","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"15","key":"10.1016\/j.gim.2021.10.013_bib35","first-page":"20","article-title":"Spectral sensitivity measurements reveal partial success in restoring missing rod function with gene therapy","volume":"15","author":"Ripamonti","year":"2015","journal-title":"J\u00a0Vis"},{"issue":"12","key":"10.1016\/j.gim.2021.10.013_bib36","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1089\/hum.2018.014","article-title":"Results at 5 years after gene therapy for RPE65-deficient retinal dystrophy","volume":"29","author":"Pennesi","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.gim.2021.10.013_bib37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.06.011","article-title":"Two-year results after AAV2-mediated gene therapy for choroideremia: the Alberta experience","volume":"193","author":"Dimopoulos","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.gim.2021.10.013_bib38","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaophthalmol.2019.3278","article-title":"Efficacy and safety of retinal gene therapy using adeno-associated virus vector for patients with choroideremia: a randomized clinical trial","volume":"137","author":"Fischer","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.gim.2021.10.013_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ajo.2018.09.012","article-title":"Choroideremia gene therapy phase 2 clinical trial: 24-month results","volume":"197","author":"Lam","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.gim.2021.10.013_bib40","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/s41591-018-0185-5","article-title":"Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia","volume":"24","author":"Xue","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/IAE.0000000000002360","article-title":"Changes in retinal sensitivity after gene therapy in choroideremia","volume":"40","author":"Fischer","year":"2020","journal-title":"Retina"},{"issue":"9923","key":"10.1016\/j.gim.2021.10.013_bib42","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib43","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaophthalmol.2016.5630","article-title":"Structural and functional recovery following limited iatrogenic macular detachment for retinal gene therapy","volume":"135","author":"Simunovic","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"11","key":"10.1016\/j.gim.2021.10.013_bib44","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2017.05.016","article-title":"Gene therapy for Leber hereditary optic neuropathy: low- and medium-dose visual results","volume":"124","author":"Guy","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.gim.2021.10.013_bib45","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ebiom.2016.07.002","article-title":"Long-term outcomes of gene therapy for the treatment of Leber\u2019s hereditary optic neuropathy","volume":"10","author":"Yang","year":"2016","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.gim.2021.10.013_bib46","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.ophtha.2017.12.036","article-title":"Safety of rAAV2\/2-ND4 gene therapy for Leber hereditary optic neuropathy","volume":"125","author":"Vignal","year":"2018","journal-title":"Ophthalmology"},{"issue":"573","key":"10.1016\/j.gim.2021.10.013_bib47","doi-asserted-by":"crossref","first-page":"eaaz7423","DOI":"10.1126\/scitranslmed.aaz7423","article-title":"Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy","volume":"12","author":"Yu-Wai-Man","year":"2020","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.gim.2021.10.013_bib48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1566523219666190618094505","article-title":"Three cases of Leber\u2019s hereditary optic neuropathy with rapid increase in visual acuity after gene therapy","volume":"19","author":"Zhang","year":"2019","journal-title":"Curr Gene Ther"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib49","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ophtha.2015.10.025","article-title":"Gene therapy for Leber hereditary optic neuropathy: initial results","volume":"123","author":"Feuer","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/WNO.0000000000000797","article-title":"Multilocus mitochondrial mutations do not directly affect the efficacy of gene therapy for Leber hereditary optic neuropathy","volume":"40","author":"Yang","year":"2020","journal-title":"J\u00a0Neuroophthalmol"},{"issue":"4","key":"10.1016\/j.gim.2021.10.013_bib51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaophthalmol.2018.6902","article-title":"Immune response and intraocular inflammation in patients with Leber hereditary optic neuropathy treated with intravitreal injection of recombinant adeno-associated virus 2 carrying the ND4 gene: a secondary analysis of a phase 1\/2 clinical trial","volume":"137","author":"Bouquet","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.gim.2021.10.013_bib52","doi-asserted-by":"crossref","first-page":"21587","DOI":"10.1038\/srep21587","article-title":"Efficacy and safety of rAAV2-ND4 treatment for Leber\u2019s hereditary optic neuropathy","volume":"6","author":"Wan","year":"2016","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","article-title":"Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR","volume":"26","author":"Cehajic-Kapetanovic","year":"2020","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00439-016-1637-y","article-title":"Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial","volume":"135","author":"Ghazi","year":"2016","journal-title":"Hum Genet"},{"issue":"6","key":"10.1016\/j.gim.2021.10.013_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaophthalmol.2020.1032","article-title":"Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial","volume":"138","author":"Fischer","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib56","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1089\/humc.2018.088","article-title":"Development of methodology and study protocol: safety and efficacy of a single subretinal injection of rAAV.hCNGA3 in patients with CNGA3-linked achromatopsia investigated in an exploratory dose-escalation trial","volume":"29","author":"Kahle","year":"2018","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"9","key":"10.1016\/j.gim.2021.10.013_bib57","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ymthe.2018.05.025","article-title":"Retinal AAV8-RS1 gene therapy for X-linked retinoschisis: initial findings from a phase I\/IIa trial by intravitreal delivery","volume":"26","author":"Cukras","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.gim.2021.10.013_bib58","first-page":"4487","article-title":"Fundus autofluorescence analysis of the transition zone in choroideremia: outcomes following gene therapy","volume":"58","author":"Dimopoulos","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1753-4887.2005.tb00127.x","article-title":"Function of the protein RPE65 in the visual cycle","volume":"63","author":"Wolf","year":"2005","journal-title":"Nutr Rev"},{"issue":"2","key":"10.1016\/j.gim.2021.10.013_bib60","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1086\/346066","article-title":"The epidemiology of Leber hereditary optic neuropathy in the North East of England","volume":"72","author":"Yu-Wai-Man","year":"2003","journal-title":"Am J Hum Genet"},{"issue":"6","key":"10.1016\/j.gim.2021.10.013_bib61","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.ophtha.2014.12.036","article-title":"Correlation of retinal structure and function in choroideremia carriers","volume":"122","author":"Edwards","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.gim.2021.10.013_bib62","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1167\/iovs.02-1206","article-title":"RPGR isoforms in photoreceptor connecting cilia and the transitional zone of motile cilia","volume":"44","author":"Hong","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib63","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/81555","article-title":"Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa","volume":"26","author":"Gal","year":"2000","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.gim.2021.10.013_bib65","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.9.7.2","article-title":"Advancing clinical trials for inherited retinal diseases: recommendations from the second Monaciano symposium","volume":"9","author":"Thompson","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"4","key":"10.1016\/j.gim.2021.10.013_bib66","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.drudis.2019.01.019","article-title":"Luxturna: FDA documents reveal the value of a costly gene therapy","volume":"24","author":"Darrow","year":"2019","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.gim.2021.10.013_bib67","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.gim.2021.10.013_bib68","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/01.opx.0000187863.12609.7b","article-title":"Reliability and consistency of visual acuity and contrast sensitivity measures in advanced eye disease","volume":"82","author":"Kiser","year":"2005","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.gim.2021.10.013_bib69","author":"Zhu"},{"key":"10.1016\/j.gim.2021.10.013_bib70","series-title":"Exploring Novel Clinical Trial Designs for Gene-Based Therapies: Proceedings of a Workshop","first-page":"41","article-title":"Developing endpoints for gene therapy clinical trials","year":"2020"},{"issue":"3","key":"10.1016\/j.gim.2021.10.013_bib71","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ceo.13022","article-title":"Novel mobility test to assess functional vision in patients with inherited retinal dystrophies","volume":"46","author":"Chung","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"issue":"8","key":"10.1016\/j.gim.2021.10.013_bib72","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1167\/tvst.9.8.25","article-title":"Harmonization of outcomes and vision endpoints in vision restoration trials: recommendations from the International HOVER taskforce","volume":"9","author":"Ayton","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"7","key":"10.1016\/j.gim.2021.10.013_bib73","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"5","key":"10.1016\/j.gim.2021.10.013_bib74","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/biom11050760","article-title":"A\u00a0systematic review and meta-analyses of interventional clinical trial studies for gene therapies for the inherited retinal degenerations (IRDs)","volume":"11","author":"Tuohy","year":"2021","journal-title":"Biomolecules"},{"issue":"suppl 1","key":"10.1016\/j.gim.2021.10.013_bib75","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1097\/IAE.0000000000002609","article-title":"Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration","volume":"39","author":"Davis","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.gim.2021.10.013_bib76","doi-asserted-by":"crossref","unstructured":"Gregori NZ, Davis JL. Surgical observations from the first 120 cases of subretinal gene therapy for inherited retinal degenerations. Retina. Published online December 18, 2020. https:\/\/doi.org\/10.1097\/IAE.0000000000003085.","DOI":"10.1097\/IAE.0000000000003085"},{"issue":"13","key":"10.1016\/j.gim.2021.10.013_bib77","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1167\/iovs.17-22473","article-title":"Superior retinal gene transfer and biodistribution profile of subretinal versus intravitreal delivery of AAV8 in nonhuman primates","volume":"58","author":"Seitz","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.gim.2021.10.013_bib78","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fnins.2017.00174","article-title":"Retinal gene therapy: surgical vector delivery in the translation to clinical trials","volume":"11","author":"Ochakovski","year":"2017","journal-title":"Front Neurosci"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002105365X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109836002105365X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:51:20Z","timestamp":1761097880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109836002105365X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S109836002105365X"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2021.10.013","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The safety and efficacy of gene therapy treatment for monogenic retinal and optic nerve diseases: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2021.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}